格隆汇1月19日｜有投资者在互动平台向美迪凯提问：请问公司募股资金投入的年产20亿颗半导体器件 项目是否已投产？该工厂主要生产哪几类产品？如果有客户需求的话，能否代工生产存储芯片元器件或 者芯片封装？ 美迪凯回复称，公司"年产20亿颗半导体器件制造项目"使用自有或自筹资金建设，目前工程建设按计划 正常推进，整体建筑工程已完工，正处于竣工验收的最后办理阶段。该项目规划的主要产品包括12英寸 MEMS器件晶圆制造及半导体封装测试等。公司当前的生产布局暂未涉及存储芯片元器件的制造。 ...

Group 1 - The company, Medike (688079.SH), currently does not produce Faraday rotators [2] - The company is attentive to downstream technology trends, including optical communication [2] - Any future business expansion will be carefully evaluated based on the company's core process platform, market demand, and customer collaboration [2]

Core Viewpoint - The company has completed the development of its entire production process for photomask substrates and has begun gradually sending samples to customers, indicating progress in certification efforts [2]. Group 1 - The company has successfully developed the complete production process for photomask substrates [2]. - The company has started to gradually deliver samples to customers as part of its certification process [2]. - The company will continue to promote the ongoing work related to photomask substrate certification [2].

Group 1 - The core point of the article is that Meidike (688079.SH) clarified that as of now, the Faraday optical plate is not part of the company's business segment or main products [1]

Group 1 - The core point of the article is that Meidike (688079.SH) clarified that as of now, the Faraday optical plate is not part of the company's business segment or main products [1]

格隆汇1月19日丨美迪凯(688079.SH)在投资者互动平台表示，公司暂未涉及OCS(光交换机)相关产品的 制造，现有 MEMS 产品与 OCS 器件在结构设计上亦有差异；但依托全流程 MEMS 微纳制造平台、12 英寸晶圆级光学薄膜及微透镜阵列加工能力，以及正在开发的 TGV 先进封装工艺，公司可为 OCS 核心 器件提供部分底层工艺支撑，并具备一定的技术储备与产业化基础。 ...

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688079 证券简称：美迪凯 公告编号：2026-002 杭州美迪凯光电科技股份有限公司 持股5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 大股东持有的基本情况 杭州美迪凯光电科技股份有限公司（以下简称"公司"）股东香港豐盛佳美（國際）投資有限公司（以下 简称"丰盛佳美"、"减持主体"）持有公司股份20,688,792股，占公司总股本的5.0346%。上述股份来源为 公司IPO前取得股份，且已于2022年3月2日解除限售并上市流通。 ● 减持计划的主要内容 减持主体计划自本公告披露之日起15个交易日后即2026年2月2日起的3个月内，减持股份不超过 4,109,297股，即不超过总股本的1.00%，均通过集中竞价方式减持，减持价格按市场价格确定。在有关 法律法规、规范性文件规定的不得减持期间内不减持股份。若在减持计划期间公司有送股、配股等股份 变动事项，减持股份数量相应调整；若公司有可转换公司债券转股 ...

来源：金综科技 公告称，本次股份减持计划系公司大股东丰盛佳美因自身资金需求而进行的正常减持行为，不会对公司 治理结构及持续经营情况产生重大影响。 此外，在减持期间内，上述减持主体将根据市场情况、公司股价等因素选择是否实施及如何实施减持计 划，本次减持计划的实施存在减持时间、减持数量、减持价格等不确定性，也存在是否按期实施完成的 不确定性。请投资者理性投资，注意投资风险。 特别声明：以上内容仅代表作者本人的观点或立场，不代表新浪财经头条的观点或立场。如因作品内 容、版权或其他问题需要与新浪财经头条联系的，请于上述内容发布后的30天内进行。 1月11日，美迪凯(688079.SH)发布公告，公司股东香港豐盛佳美(國際)投資有限公司(简称"丰盛佳美")计 划自公告披露之日起15个交易日后即2026年2月2日起的3个月内，减持股份不超过410.93万股，即不超 过总股本的1%。 ...

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]